• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BTIG Research initiated coverage on Gain Therapeutics with a new price target

    4/12/21 6:40:49 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GANX alert in real time by email
    BTIG Research initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $30.00
    Get the next $GANX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GANX

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    More analyst ratings

    $GANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Gain Therapeutics with a new price target

    Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    3/7/25 8:20:06 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Gain Therapeutics with a new price target

    ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/24 7:48:38 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Gain Therapeutics with a new price target

    Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

    8/14/24 7:36:01 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

    BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule therapies, today announced that Dr. Rinaldo Montalvão, Director of Artificial Intelligence at Gain Therapeutics, will deliver a talk at the WORLD BI sponsored Drug Discovery Innovation Programme (DDIP) 2025, being held September 25th -26th in Barcelona, Spain. Details on the talk are as follows: Track: AI and Automation in Drug Discovery Title: "Transforming Drug Discovery: Generative Models and Electrostatic Complementarity" Date: Friday, Sept

    9/23/25 7:40:39 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

    Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled 21 subjects and the last participants will complete 90 days of dosing in December 2025 Early results from the Phase 1b study to be presented at the International Congress of Parkinson's Disease (PD) and Movement Disorders in October BETHESDA, Md., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, tod

    9/18/25 7:41:59 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

    Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no changes to study design BETHESDA, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the Company has received approval from the Bellberry Human Research Ethics Committee and Alfred Hospital Ethics Committee to extend dosing

    9/4/25 8:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:31 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:30 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    7/1/24 5:00:27 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    SEC Filings

    View All

    SEC Form 10-Q filed by Gain Therapeutics Inc.

    10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)

    8/12/25 4:05:39 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

    8/12/25 4:03:31 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Gain Therapeutics Inc.

    424B5 - Gain Therapeutics, Inc. (0001819411) (Filer)

    7/17/25 7:37:20 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Islam Khalid

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:23 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Richman Eric I

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:19 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nicaise Claude

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:22 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Leadership Updates

    Live Leadership Updates

    View All

    Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

    Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

    1/7/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

    Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

    6/27/24 4:08:08 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

    BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

    4/8/24 9:25:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Financials

    Live finance-specific insights

    View All

    Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

    BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

    5/14/25 7:30:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

    BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

    3/27/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

    BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

    11/14/24 4:05:00 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gain Therapeutics Inc.

    SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

    3/29/21 11:59:04 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care